Immuneering Corp
NASDAQ:IMRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Boa Safra Sementes SA
BOVESPA:SOJA3
|
BR |
|
Why How Do Co Inc
TSE:3823
|
JP |
|
Brinker International Inc
NYSE:EAT
|
US |
|
G
|
Gander Gold Corp
CNSX:GAND
|
CA |
|
Super House Ltd
NSE:SUPERHOUSE
|
IN |
|
V
|
Vikas Lifecare Ltd
BSE:542655
|
IN |
Immuneering Corp
Total Receivables
Immuneering Corp
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Immuneering Corp
NASDAQ:IMRX
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$2.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Immuneering Corp
Glance View
Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.
